期刊
EXPERT OPINION ON DRUG SAFETY
卷 12, 期 4, 页码 581-588出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.2013.798299
关键词
leflunomide; rheumatoid arthritis; toxicity
Introduction: Leflunomide is a prodrug which is rapidly converted following oral administration and absorption to an active metabolite with antiproliferative effects (A77 1726/teriflunomide). Leflunomide was developed as an immunomodulatory agent and subsequently developed as a disease-modifying anti-rheumatic drug (DMARD) for the management of rheumatoid arthritis (RA). Areas covered: This review article covers the mechanism of action of the drug, clinical indications, including efficacy data from clinical trials, safety data from clinical trials, post marketing studies and surveillance databases and safety in special populations. Additionally, the review discusses the current place of leflunomide in the management of RA, and its likely future as an antirheumatic drug. Expert opinion: Leflunomide is a relatively safe drug, with proven efficacy in RA management. Its clinical use is limited by the historic parallel development of other agents, including methotrexate, which has become the synthetic DMARD of choice and biological DMARDs that have superior efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据